Tag: NewAmsterdam Pharma

New Review Article in ESC’s Cardiovascular Research Examines Cholesteryl Ester Transfer Protein (CETP) Inhibition’s Role in Reducing Cardiovascular Disease Risk

Coronary/Structural Heart by 0 comments

NAARDEN, Netherlands–(BUSINESS WIRE)–NewAmsterdam Pharma (NAP), a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases, today announced the publication of a new review article in the European Society of Cardiology (ESC) publication Cardiovascular Research examining cholesteryl ester transfer protein […]

Continue Reading →

NewAmsterdam Pharma Doses First Patient in Phase 3 BROADWAY Trial of Obicetrapib in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) and/or Established Atherosclerotic Cardiovascular Disease (ASCVD)

Coronary/Structural Heart by 0 comments

Study evaluates obicetrapib, a novel cholesteryl ester transfer protein (CETP) inhibitor, as an adjunct to diet and maximally tolerated lipid-lowering therapy Company is expected to complete enrollment in 2022 and announce data in the first quarter of 2024 NAARDEN, Netherlands–(BUSINESS […]

Continue Reading →
1 2